Injection Devices for Biological Drugs, 2018 Report - Opportunity in Unmet Patient Needs, Device Material Selection Factors, Biosimilars & The Biological Drug Global Supply Chain

DUBLIN, Oct. 5, 2018 /PRNewswire/ --

The "Injection Devices for Biological Drugs" report has been added to ResearchAndMarkets.com's offering.

Biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition.

The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.

New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

Injection Devices for Biological Drugs - What You Will Learn

• What are the product and user requirements that drive the biological drug-device selection process?
• What are the essential design factors, technologies and market development issues for injection devices capable of administering biological dugs?
• What is the impact of development-stage biological manufacturing process changes on device go-to-market readiness and how has it changed in recent years?
• How do device selection decisions align across biological drug classes? Therapeutic targets? Market segments?
• What is the impact of drug-device dependencies on pre- and post-marketing product life cycle management?
• What are the significant economic, technology, and regulatory factors affecting the market for biological drug injection devices?

Key Topics Covered:

1.0 Executive Summary

2.0 The Market Opportunity

2.1 Unmet Patient Needs
2.2 Device Material Selection Factors
2.3 Biosimilars
2.4 The Biological Drug Global Supply Chain

3.0 Biological Drug Delivery - Challenges and Limitations

3.1 Drug Stability
3.2 Pre- and Post-Manufacturing Engineering
3.3 Lyophilization and Reconstitution
3.4 Viscosities and Volumes

4.0 Drug Strategies & Therapeutic Protein Packaging

4.1 As-Supplied Packaging
4.2 Device Market Share
4.3 Device Supplier Segment Activity
4.4 Emerging Injection Devices for Biological Drugs

5.0 Injectable Biologicals - Product Analysis by Drug Class

5.1 Cytokines
5.2 Enzymes
5.3 Fusion Proteins
5.4 G-CSF/GM-CSF
5.5 Hematopoietics
5.6 Hormones
5.7 Immune Modulators
5.8 Insulins & GLP Analogs
5.9 Monoclonal Antibodies
5.10 Vaccines

6.0 Therapeutic Market Segment Analysis

6.1 Cardiovascular
6.2 Diabetes
6.3 Hematology
6.4 Immunology
6.5 Metabolic
6.6 Oncology

7.0 Market Factors

7.1 Regulatory Issues
7.2 Patient Preferences and Self-Administration
7.3 Pre- and Post-marketing Device Evolution
7.4 Compatibility Testing

8.0 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/lf4dnh/injection_devices?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/injection-devices-for-biological-drugs-2018-report---opportunity-in-unmet-patient-needs-device-material-selection-factors-biosimilars--the-biological-drug-global-supply-chain-300725267.html

SOURCE Research and Markets